Totus Medicines has entered into a multi-target research collaboration with Eli Lilly and Company to discover small molecule drug candidates against undisclosed targets. Under the terms of the agreement, Totus Medicines will use its proprietary OmniDEL platform to generate high-quality covalent compounds against Lilly targets. Subsequently, Lilly and Totus will have options to exclusively pursue preclinical and clinical development and commercialization of compounds identified from the collaboration and receive milestone payments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly announces retirement of Chief Ethics and Compliance Officer Weems
- New Analyst Adjustments Prove Little Help to Eli Lilly (NYSE:LLY)
- Eli Lilly price target raised to $840 from $770 at Argus
- Cipla Wants to Partner with Eli Lilly (NYSE:LLY) in India
- Rani Therapeutics price target raised to $14 from $7 at BTIG